Sickle cell disease

Pediatric Clinics of North America

Volumn 49, Issue 6, 2002, Pages 1193-1210

  Fixler, Jason ^a   Styles, Lori ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; AZITHROMYCIN; BENZODIAZEPINE DERIVATIVE; CEFOTAXIME; CODEINE; DIHYDROMORPHINE; DIPHENHYDRAMINE; ERYTHROMYCIN; HYDROXYUREA; INFLUENZA VACCINE; INFUSION FLUID; LORAZEPAM; MACROLIDE; MORPHINE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN DERIVATIVE; PETHIDINE; PNEUMOCOCCUS VACCINE;

ACUTE CHEST SYNDROME; ANEMIA; AVASCULAR NECROSIS; CHILD; CHOLELITHIASIS; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; EYE DISEASE; GENETICS; HUMAN; INFECTION; KIDNEY DISEASE; NEUROLOGICAL COMPLICATION; PAIN; REVIEW; SEIZURE; SICKLE CELL ANEMIA; SPLEEN; STEM CELL TRANSPLANTATION; UROGENITAL TRACT DISEASE;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CHILD; HUMANS; HYDROXYUREA; STEM CELL TRANSPLANTATION;

EID: 0036974378     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(02)00089-5     Document Type: Review

References (106)

1. Clinical Practice Guideline Number 6: sickle cell disease. Screening, diagnosis, management, and counseling in newborns and infants. Publication N. 93-0562. Silver Springs, Maryland: Agency for Health Care Policy and Research; 1993.
2. Motulsky AG. Frequency of sickling disorders in U.S. blacks. N Engl J Med 1973;288:31-3.
3. Roth Jr EF, Friedman M, Ueda Y, et al. Sickling rates of human AS red cells infected in vitro with Plasmodium falciparum malaria. Science 1978;202:650-2.
4. Serjeant GR. Natural history and determinants of clinical severity of sickle cell disease. Curr Opin Hematol 1995;2:103-8.
5. Serjeant GR. Sickle-cell disease. Lancet 1997;350:725-30.
6. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Sickle cell disease: basic principles and clinical practice. New York: Raven Press; 1994.
7. Ballas SK, Mohandas N. Pathophysiology of vaso-occlusion. Hematol Oncol Clin N Am 1996;10:1221-39.
8. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-9.
9. Hebbel RP. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. Journal of Clinical Investigation 1997;99:2561-4.
10. Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985;76:392-7.
11. Wright J, Thomas P, Serjeant GR. Septicemia caused by Salmonella infection: an overlooked complication of sickle cell disease. J Pediatr 1997;130:394-9.
12. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995;86:776-83.
13. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986;314:1593-9.
14. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995;127:685-90.
15. Morris C, Vichinsky E, Styles L. Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? Ann Emerg Med 1999;34:64-9.
16. Wilimas JA, Flynn PM, Harris S, et al. A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med 1993;329:472-6.
17. Williams LL, Wilimas JA, Harris SC, et al. Outpatient therapy with ceftriaxone and oral cefixime for selected febrile children with sickle cell disease. J Pediatr Hematol Oncol 1996;18:257-61.
18. Hongeng S, Wilimas JA, Harris S, et al. Recurrent Streptococcus pneumoniae sepsis in children with sickle cell disease. J Pediatr 1996;130:814-6.
19. Ballas SK, Lamer J, Smith ED, et al. Rheologic predictors of the severity of the painful sickle cell crisis. Blood 1988;72:1216-23.
20. Guidelines for the management of acute and chronic pain in sickle-cell disease. Glenview, : American Pain Society; 1999.
21. Ballas SK, Carlos TM, Dampier C, and the Guidelines Committee. Guidelines for standard of care of acute painful episodes in patients with sickle cell disease. Philadelphia: Cardeza Foundation; 2000.
22. Hagmeyer KO, Mauro LS, Mauro VF. Meperidine-related seizures associated with patient-controlled analgesia pumps. Ann Pharmacother 1993;27:29-32.
23. McPherson E, Perlin E, Finke H, et al. Patient-controlled analgesia in patients with sickle cell vaso-occlusive crisis. Am J Med Sci 1990;299:10-2.
24. Schechter NL, Berrien FB, Katz SM. The use of patient-controlled analgesia in adolescents with sickle cell pain crisis: a preliminary report. J Pain Symptom Manage 1988;3:109-13.
25. Shapiro BS, Cohen DE, Howe CJ. Patient-controlled analgesia for sickle-cell-related pain. J Pain Symptom Manage 1993;8:22-8.
26. Gray A, Anionwu EN, Davies SC, Brozovic M. Patterns of mortality in sickle cell disease in the United Kingdom. J Clin Pathol. 1991;44:459-63.
27. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
28. Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol 1991;28:220-6.
29. Charache S, Scott JC, Charache P. "Acute chest syndrome" in adults with sickle cell anemia. Arch Intern Med 1979;139:67-9.
30. Vichinsky EP, Styles LA, Colangelo LH, et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997;89:1787-92.
31. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med 2000; 342:1855-65.
32. Johnson K, Stastny JF, Rucknagel DL. Fat embolism syndrome associated with asthma and sickle cell=Β+-thalassemia. Am J Hematol 1994;46:354-7.
33. Vichinsky EP, Williams R, Das M, et al. Pulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood 1994;83:3107-12.
34. Blaisdell CJ, Goodman S, Clark K, et al. Pulse oximetry is a poor predictor of hypoxemia in stable children with sickle cell disease. Arch Pediatr Adolesc Med 2000;154:900-3.
35. Bellet PS, Kalinyak KA, Shukla R, et al. Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med 1995;333:699-703.
36. Powars D, Weidman JA, Odom-Maryon T, et al. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988;67:66-76.
37. Pegelow CH, Macklin EA, Moser FG, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood 2002;99:3014-8.
38. Miller ST, Macklin EA, Pegelow CH, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of Sickle Cell Disease. J Pediatr 2001;139:385-90.
39. Wang W, Riester K, Gallagher D, et al. Progressive neurocognitive deficits occur in school-age children with sickle cell disease (SCD) in the absence of clinical or MRI evidence of infarction. 23rd Annual Meeting of the National Sickle Cell Disease Program. San Francisco, CA, March 5-9, 1999.
40. Armstrong FD, Thompson RJ, Wang W, et al. Cognitive functioning and brain magnetic resonance imaging in children with sickle cell disease. Pediatrics 1996;97:864-70.
41. Stockman JA, Nigro MA, Mishkin MM, et al. Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med 1972;287:846-9.
42. Merkel KH, Ginsberg P, Parker J, et al. Cerebrovascular disease in sickle cell anemia: a clinical, pathological and radiological correlation. Stroke 1978;9:45-52.
43. Powars D, Wilson B, Imbus C, et al. The natural history of stroke in sickle cell disease. Am J Med 1978;65:461-71.
44. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94.
45. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics 1999;103:640-5.
46. Adams R, McKie V, Nichols F, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605-10.
47. Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials 1998;19:110-29.
48. Serjeant GR, Serjeant BE, Thomas PW, et al. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993;341:1237-40.
49. Lowenthal EA, Wells A, Emanuel PD, et al. Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Am J Hematol 1996;51:207-13.
50. Kolquist KA, Vnencak-Jones CL, Swift L, et al. Fatal fat embolism syndrome in a child with undiagnosed hemoglobin S-beta+ thalassemia: a complication of acute parvovirus B19 infection. Pediatr Pathol Lab Med 1996;16:71-82.
51. Godeau B, Galacteros F, Schaeffer A, et al. Aplastic crisis due to extensive bone marrow necrosis and human parvovirus infection in sickle cell disease. Am J Med 1991;91:557-8.
52. Statius van Eps LW, Pinedo-Veels C, de Vries GH, et al. Nature of concentrating defect in sickle-cell nephropathy. Microradioangiographic studies. Lancet 1970;1:450-2.
53. Lucas WM. Hematuria in sickle cell disease. J Urol 1960;83:733-41.
54. Falk RJ, Scheinman J, Phillips G, et al. Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. N Engl J Med 1992;326:910-5.
55. Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 1999;21:518-22.
56. Hamre MR, Harmon EP, Kirkpatrick DV, et al. Priapism as a complication of sickle cell disease. J Urol 1991;145:1-5.
57. Powars DR, Johnson CS. Priapism. Hematol Oncol Clin N Am 1996;10:1363-72.
58. Rackoff WR, Ohene-Frempong K, Month S, et al. Neurologic events after partial exchange transfusion for priapism in sickle cell disease [see comments]. J Pediatr 1992;120:882-5.
59. Seeler RA. Priapism in children with sickle cell anemia. Clin Pediatr 1971;10:418-9.
60. Mantadakis E, Ewalt DH, Cavender JD, et al. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood 2000;95:78-82.
61. Baruchel S, Rees J, Bernstein ML, Goodyer P. Relief of sickle cell priapism by hydralazine. Report of a case. Am J Pediatr Hematol Oncol 1993;15:115-6.
62. Virag R, Bachir D, Lee K, Galacteros F. Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology 1996;47:777-81.
63. Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology 2002; 59:138.
64. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991;325:1476-81.
65. Onuba O. Bone disorders in sickle-cell disease. Int Orthop 1993;17:397-9.
66. Ware HE, Brooks AP, Toye R, et al. Sickle cell disease and silent avascular necrosis of the hip. J Bone Joint Surg Br 1991;73:947-9.
67. Styles LA, Vichinsky EP. Core decompression in avascular necrosis of the hip in sickle-cell disease. Am J Hematol 1996;52:103-7.
68. Stulberg BN, Davis AW, Bauer TW, et al. Osteonecrosis of the femoral head. A prospective randomized treatment protocol. Clin Orthop 1991;268:140-51.
69. Vichinsky EP, Neumayr LD, Haberkern C, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. Am J Hematol 1999;62:129-38.
70. Garden MS, Grant RE, Jebraili S. Perioperative complications in patients with sickle cell disease. An orthopedic perspective. Am J Orthop 1996;25:353-6.
71. Acurio MT, Friedman RJ. Hip arthroplasty in patients with sickle-cell haemoglobinopathy. J Bone Joint Surg Br 1992;74:367-71.
72. Samaik S, Slovis TL, Corbett DP, et al. Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique. J Pediatr 1980;96:1005-8.
73. Ware RE, Schultz WH, Filston HC, et al. Diagnosis and management of common bile duct stones in patients with sickle hemoglobinopathies. J Pediatr Surg 1992;27:572-5.
74. Duncan ND, Smith AI, McDonald AH, et al. Biliary surgery in sickle cell disease: the Jamaican experience. J R Coll Surg Edinb 2002;47:414-7.
75. Serjeant BE, Mason KP, Acheson RW, et al. Blood theology and proliferative retinopathy in homozygous sickle cell disease. Br J Ophthalmol 1986;70:522-5.
76. Koduri PR, Agbemadzo B, Nathan S. Hemoglobin S-C disease revisited: clinical study of 106 adults. Am J Hematol 2001;68:298-300.
77. Ballas SK. Complications of sickle cell anemia in adults: guidelines for effective management. Cleve Clin J Med 1999;66:48-58.
78. Charache S. Eye disease in sickling disorders. Hematol Oncol Clin N Am 1996;10:1357-62.
79. Health supervision for children with sickle cell disease. Pediatrics 2002;109:526-35.
80. Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med 1984;311:7-12.
81. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group [see comments]. N Engl J Med 1995;333:206-13.
82. Talano JM, Johnston ST, et al. Partial phenotype matching (RH, KE11) reduces alloimmunization in children with Sickle Cell Disease (SCD). J Pediatr Hematol Oncol 2000;22:369-70.
83. Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41:1086-92.
84. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol 2001;38:14-22.
85. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000;96:3369-73.
86. Eckman JR. Techniques for blood administration in sickle cell patients. Semin Hematol 2001; 38:23-9.
87. Charache S. The treatment of sickle cell anemia. Arch Intern Med 1974;133:698-705.
88. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
89. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology (Am Soc Hematol Educ Prog) 2001:47-61.
90. Adams DM, Schultz WH, Ware RE, et al. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J pediatr Hematol Oncol 1996;18:46-50.
91. Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994;83:1136-42.
92. Singer ST, Quirolo K, Nishi K, et al. Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apheresis 1999;14:122-5.
93. Vichinsky EP, Earles A, Johnson RA, et al. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617-21.
94. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996;75:300-26.
95. Styles LA, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997;89:2554-9.
96. Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989;32:104-11.
97. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-22.
98. Hoppe C, Vichinsky E, Quirolo K, et al. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol 2000;22:330-4.
99. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996;88:1960-4.
100. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-65.
101. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood 1999;94:1550-4.
102. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996;128:820-8.
103. Wang W, Wynn L, Rogers Z, et al. Effects of hydroxyurea in very young children with sickle cell disease: a pilot trial. 23rd Annual Meeting of the National Sickle Cell Disease Program. San Francisco, March 6-9; 1999. p. 167.
104. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-76.
105. Walters MC, Patience M, Leisenring W, et al. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant 1997;3:310-5.
106. Walters MC. Bone marrow transplantation for sickle cell disease: where do we go from here? J Pediatr Hematol Oncol 1999;21:467-74.